Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

IBD IN 2019

Host–microbiota interactions in inflammatory bowel disease

Nature Reviews Gastroenterology & Hepatology volume 17, pages 76–77 (2020)Cite this article

Subjects

Key studies published in 2019 highlight novel concepts regarding the pathogenesis of inflammatory bowel disease: the emerging role of host–microorganism interactions and the regional microbiota as disease drivers, and the identification of new therapeutic targets. These findings suggest new avenues for research and define important hallmarks for clinical diagnosis and therapy.

Key advances

  • Specific microbial pathways control intestinal epithelial cell and barrier function and determine responsiveness to anti-TNF therapy, suggesting that targeting of these pathways is relevant for inflammatory bowel disease (IBD) therapy3; increased Bifidobacterium, Collinsella, Lachnospira, Lachnospiraceae, Roseburia and Eggerthella taxa are related to successful outcome (clinical response or remission) of anti-TNF therapy in Crohn’s disease.

  • Many defined microbial metabolites are depleted in individuals with IBD versus control individuals, indicating that loss of metabolic diversity occurs with dysbiosis and loss of taxonomic diversity in the IBD microbiome4.

  • The transcription factor c-MAF is a key factor in gut regulatory T cells that maintains host–microorganism homeostasis and prevents gut inflammation5.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Intestinal barrier alterations in IBD.

References

  1. Sands, B. E. et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 381, 1201–1214 (2019).

    Article  CAS  Google Scholar 

  2. Neurath, M. F. Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat. Immunol. 20, 970–979 (2019).

    Article  CAS  Google Scholar 

  3. Yilmaz, B. et al. Microbial network disturbances in relapsing refractory Crohn’s disease. Nat. Med. 25, 323–336 (2019).

    Article  CAS  Google Scholar 

  4. Franzosa, E. A. et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat. Microbiol. 4, 293–305 (2019).

    Article  CAS  Google Scholar 

  5. Neumann, C. et al. c-Maf-dependent Treg cell control of intestinal TH17 cells and IgA establishes host-microbiota homeostasis. Nat. Immunol. 20, 471–481 (2019).

    Article  CAS  Google Scholar 

  6. Arpaia, N. et al. Metabolites produced by commensal bacteria promote peripheral regulatory T cell generation. Nature 504, 451–455 (2013).

    Article  CAS  Google Scholar 

  7. Furusawa, Y. et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504, 446–450 (2013).

    Article  CAS  Google Scholar 

  8. Sujino, T. et al. Regulatory T cells suppress development of colitis, blocking differentiation of T-helper 17 into alternative T-helper 1 cells. Gastroenterology 141, 1014–023 (2011).

    Article  CAS  Google Scholar 

  9. Maul, J. et al. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology 128, 1868–1878 (2005).

    Article  CAS  Google Scholar 

  10. Zundler, S. et al. Hobit- and Blimp-1-driven CD4+ tissue-resident memory T cells control chronic intestinal inflammation. Nat. Immunol. 20, 288–300 (2019).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

M.F.N. is supported by the Clinical Research Group 257 CEDER, the SFB1181, the TRR241, the FOR2438 of the Deutsche Forschungsgemeinschaft, the Interdisciplinary Center for Clinical Research (IZKF) and the Emerging Fields Initiative of the Friedrich Alexander Universität Erlangen-Nürnberg.

Author information

Authors and Affiliations

  1. Department of Medicine, University of Erlangen-Nuremberg, Kussmaul Campus for Medical Research, Erlangen, Germany

    Markus F. Neurath

  2. Deutsches Zentrum Immuntherapie (DZI), Erlangen, Germany

    Markus F. Neurath

  3. Ludwig Demling Endoscopy Center of Excellence, Erlangen, Germany

    Markus F. Neurath

Authors
  1. Markus F. Neurath
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markus F. Neurath.

Ethics declarations

Competing interests

M.F.N. has served as an adviser or received research grants from Abbvie, Amgen, Boehringer, Janssen, MSD, Pentax, Pfizer, PPM, Roche and Takeda.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Neurath, M.F. Host–microbiota interactions in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 17, 76–77 (2020). https://doi.org/10.1038/s41575-019-0248-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41575-019-0248-1

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing